(naf AZ oh leen)
Note: Not approved in US and/or Canada
Nasal congestion: Temporary relief of nasal congestion associated with the common cold, upper respiratory allergies, or rhinitis/sinusitis
Hypersensitivity to naphazoline, other adrenergic agonists, or any component of the formulation; angle-closure glaucoma; children <12 years; oral inhalation
Nasal congestion (decongestant): Intranasal: 0.05%: Instill 2 to 4 drops in each nostril 4 to 6 times daily (maximum daily dose: 48 drops). Avoid continuous use for >5 days.
Refer to adult dosing.
Nasal congestion (decongestant): Intranasal: Children ≥12 years and Adolescents: Refer to adult dosing.
There are no dosage adjustments provided in the manufacturers labeling
There are no dosage adjustments provided in the manufacturers labeling
Intranasal: For intranasal use only. Allow at least 3 hours between successive administrations.
Store at room temperature of 15 ‚ °C to 30 ‚ °C (59 ‚ °F to 86 ‚ °F); Protect from light.
Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy
Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Monitor therapy
Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. Exceptions: Ergoloid Mesylates; Nicergoline. Avoid combination
FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. Monitor therapy
Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. Avoid combination
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification
MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid; Tedizolid. Avoid combination
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists. Monitor therapy
Concerns related to adverse effects:
- Rebound nasal congestion: May occur with extended use.
Disease-related concerns:
- Cardiovascular disease: Use with caution in patients with hypertension, heart failure, or coronary artery disease.
- Diabetes: Use with caution in patients with diabetes mellitus.
- Hyperthyroidism: Use with caution in patients with hyperthyroidism.
- Prostatic hyperplasia: Use with caution in patients with benign prostatic hyperplasia.
Concurrent drug therapy issues:
- Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
Other warnings/precautions:
- Accidental ingestion: Accidental ingestion by children of over-the-counter (OTC) imidazoline-derivative eye drops and nasal sprays may result in serious harm. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children ≤5 years of age who had ingested even small amounts (eg, 1-2 mL). Contact a poison control center and seek emergency medical care immediately for accidental ingestion (FDA Drug Safety Communication, 2012).
Stimulates alpha-adrenergic receptors in the arterioles of the conjunctiva and the nasal mucosa to produce vasoconstriction